639784-19-3

Basic information

• Product Name: 2-(4-BROMOMETHYL-2, 6-DIMETHYL-PHENOXY)-2-METHYL-PROPIONIC asid ethyl ester
• Synonyms: 2-(4-BROMOMETHYL-2, 6-DIMETHYL-PHENOXY)-2-METHYL-PROPIONIC asid ethyl ester
• CAS NO: 639784-19-3
• Molecular Weight: 329.234
• Mol File: 639784-19-3.mol

Chemical Properties

• CAS DataBase Reference: 2-(4-BROMOMETHYL-2, 6-DIMETHYL-PHENOXY)-2-METHYL-PROPIONIC asid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BROMOMETHYL-2, 6-DIMETHYL-PHENOXY)-2-METHYL-PROPIONIC asid ethyl ester(639784-19-3)
• EPA Substance Registry System: 2-(4-BROMOMETHYL-2, 6-DIMETHYL-PHENOXY)-2-METHYL-PROPIONIC asid ethyl ester(639784-19-3)

Safety Data

• Hazardous Substances Data: 639784-19-3(Hazardous Substances Data)

Upstream product

• 2233-18-3 4-hydroxy-3,5-dimethylbenzaldehyde 
• 639784-17-1 ethyl 2-(4-formyl-2,6-dimethylphenoxy)-2-methylpropanoate 
• 639784-18-2 2-(4-HYDROXY-2, 6-DIMETHYL-PHENOXY)-2-METHYL-PROPIONIC acid ethyl ester 

Downstream Products

• 639783-41-8 2-[2, 6-DIMETHYL-4-({[4-METHYL-2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOL-5-YL]-THIOPHEN-3-YIMETHYL-AMINO}-METHYL)-PHENOXY]-2-METHYL-PROPIONIC ACID 

Relevant articles and documents

Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms

Diabetic kidney disease (DKD) is a major feature of the final stage of nearly all cause types of diabetes mellitus (DM). To date, few safe and effective drugs are available to treat. Peroxisome proliferator-activated receptors (PPARs), comprised of three members: PPAR-α, PPAR-δ and PPAR-γ, play a protective role in the DKD through glycemic control and lipid metabolism, whereas systemic activation of PPAR-γ causes serious side-effects in clinical trials. GFT505 is a dual PPAR-α/δ agonist, and the selectivity against PPAR-γ is still to be improved. Sulfuretin has been shown to suppress the expression of PPAR-γ and improve the pathogenesis of diabetic complications. In this study, by hybridizing the carboxylic acid of GFT505 and the parent nucleus of sulfuretin, we pioneeringly designed and synthetized a series of novel dual PPAR-α/δ agonists, expecting to provide a better benefit/risk ratio for PPARs. Of all the synthesized compounds, compound 12 was identified with highly activity on PPAR-α/δ and higher selectivity against PPAR-γ than that of GFT505 (EC50: hPPAR-α: 0.26 μM vs.0.76 μM; hPPAR-δ: 0.50 μM vs.0.73 μM; hPPAR-γ: 4.22 μM vs.2.79 μM). The molecular docking studies also depicted good binding affinity of compound 12 for PPAR-α and PPAR-δ compared to GFT505. Furthermore, compound 12 exhibited an evidently renoprotective effect on the DKD through inhibiting inflammatory process, which might at least partly via JNK/NF-κB pathways in vivo and in vitro. Overall, compound 12 hold therapeutic promise for DKD.

CHEMICAL COMPOUNDS

A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein: (...).